|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2005-5-17
|
|
pubmed:abstractText |
To determine the tolerability and pharmacokinetics of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, administered over 14 consecutive days of a 21-day cycle.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BycottPaulP,
pubmed-author:CunninghamCaseyC,
pubmed-author:EisemanIreneI,
pubmed-author:LenehanPeter FPF,
pubmed-author:NemunaitisJohnJ,
pubmed-author:OlsonStephen CSC,
pubmed-author:SchlichtMichaelM,
pubmed-author:SenzerNeilN,
pubmed-author:ShinDong MDM,
pubmed-author:WilliamsAdrienneA,
pubmed-author:ZentgraffRebeccaR,
pubmed-author:ZinnerRalph GRG
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3846-53
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:15897585-Adult,
pubmed-meshheading:15897585-Aged,
pubmed-meshheading:15897585-Aged, 80 and over,
pubmed-meshheading:15897585-Anorexia,
pubmed-meshheading:15897585-Diarrhea,
pubmed-meshheading:15897585-Drug Administration Schedule,
pubmed-meshheading:15897585-Exanthema,
pubmed-meshheading:15897585-Female,
pubmed-meshheading:15897585-Humans,
pubmed-meshheading:15897585-Male,
pubmed-meshheading:15897585-Maximum Tolerated Dose,
pubmed-meshheading:15897585-Middle Aged,
pubmed-meshheading:15897585-Morpholines,
pubmed-meshheading:15897585-Neoplasms,
pubmed-meshheading:15897585-Protein-Tyrosine Kinases
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer.
|
|
pubmed:affiliation |
Mary Crowley Medical Research Center/Texas Oncology PA, Dallas, Texas, USA. jnemunaitis@mcmrc.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase I
|
